DTIL / Precision BioSciences' (DTIL) Stock Up This Week: Here's Why

The heavy selling pressure might have exhausted for Precision BioSciences (DTIL) as it is technically in oversold territory now. In addition to this t more_horizontal

Precision BioSciences (DTIL) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares t more_horizontal

Precision Biosciences has been on a roll with positive updates in both their CAR T-Cell and gene editing pipelines. Unfortunately, the market has yet more_horizontal

Precision BioSciences (DTIL) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares t more_horizontal

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -8.33% and 78%, respectively, for the quarter ended December 2022. Do the num more_horizontal

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allog more_horizontal

Precision BioSciences has been on the candidate list for my Compounding Healthcare “Bio Boom” Portfolio. I am looking to find a spot for DTIL ahea more_horizontal

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -2.33% and 23.80%, respectively, for the quarter ended June 2022. Do the numb more_horizontal